The intracellular delivery of enzymes is an essential methodology to extend their therapeutic application. Herein, we have developed dissociable supermolecule-enzyme polyelectrolyte complexes based on reduction-cleavable cationic polyrotaxanes (PRXs) for the reactivation of delivered enzymes. These PRXs are characterized by their supramolecular frameworks of a polymeric chain threading into cyclic molecules, which can form polyelectrolyte complexes with anionic enzymes while retaining their three dimensional structure, although their enzymatic activity is reduced. Upon the addition of a reductant, the PRXs dissociate into their constituent molecules and release the enzymes, resulting in a complete recovery of enzymatic activity. Under the intracellular environment, the PRX-based enzyme complexes showed the highest intracellular enzymatic activity and efficient activation of anticancer prodrugs to induce cytotoxic effects in comparison with the non-dissociable complexes and the commercial cell-penetrating peptide-based reagents. Thus, the intracellularly dissociable supermolecules are an attractive system for delivering therapeutic enzymes into living cells. P rotein therapeutics have received tremendous attention, and more than 100 protein therapeutics including antibodies, enzymes and peptides, are currently approved for clinical use 1,2 . Of these, enzymes are of significance in therapeutic approaches such as the enzyme replacement therapy and the enzyme-prodrug therapy 3,4 . Although these therapeutic approaches require cellular internalization of therapeutic enzymes, most of the enzymes have low ability to cross the cellular membrane, resulting in insufficient therapeutic efficacy 5 . To address this problem, cell-penetrating peptides (CPPs) are chemically or genetically linked to enzymes to improve in vitro and in vivo delivery 5-7 . Another promising approach for intracellular protein delivery is complex formation with polymeric materials or encapsulation in nanoparticles [8] [9] [10] [11] . However, complex formation with polymers through electrostatic or hydrophobic interactions often causes a loss of the activity of the enzymes, most likely due to the mask of active site 12 . To regulate the enzymatic activity, various methodologies that can control the association and dissociation of the complexes have been achieved by using pH 13 , electric fields 14 , salt concentrations 15 , the addition of polyelectrolytes 16, 17 , and other additives 18 . Although these methodologies are effective at regulating the enzymatic activity in response to physical or chemical stimuli to a certain extent, the potential of intracellular delivery and enzymatic control in intracellular environments is not yet known. Because the intracellular activity of enzymes plays a crucial role in enzyme-based therapy, strategies for molecular logistics are required to show efficient intracellular delivery as well as enhanced enzymatic activity in the intracellular environment.
The intracellular delivery of enzymes is an essential methodology to extend their therapeutic application. Herein, we have developed dissociable supermolecule-enzyme polyelectrolyte complexes based on reduction-cleavable cationic polyrotaxanes (PRXs) for the reactivation of delivered enzymes. These PRXs are characterized by their supramolecular frameworks of a polymeric chain threading into cyclic molecules, which can form polyelectrolyte complexes with anionic enzymes while retaining their three dimensional structure, although their enzymatic activity is reduced. Upon the addition of a reductant, the PRXs dissociate into their constituent molecules and release the enzymes, resulting in a complete recovery of enzymatic activity. Under the intracellular environment, the PRX-based enzyme complexes showed the highest intracellular enzymatic activity and efficient activation of anticancer prodrugs to induce cytotoxic effects in comparison with the non-dissociable complexes and the commercial cell-penetrating peptide-based reagents. Thus, the intracellularly dissociable supermolecules are an attractive system for delivering therapeutic enzymes into living cells. P rotein therapeutics have received tremendous attention, and more than 100 protein therapeutics including antibodies, enzymes and peptides, are currently approved for clinical use 1, 2 . Of these, enzymes are of significance in therapeutic approaches such as the enzyme replacement therapy and the enzyme-prodrug therapy 3, 4 . Although these therapeutic approaches require cellular internalization of therapeutic enzymes, most of the enzymes have low ability to cross the cellular membrane, resulting in insufficient therapeutic efficacy 5 . To address this problem, cell-penetrating peptides (CPPs) are chemically or genetically linked to enzymes to improve in vitro and in vivo delivery [5] [6] [7] . Another promising approach for intracellular protein delivery is complex formation with polymeric materials or encapsulation in nanoparticles [8] [9] [10] [11] . However, complex formation with polymers through electrostatic or hydrophobic interactions often causes a loss of the activity of the enzymes, most likely due to the mask of active site 12 . To regulate the enzymatic activity, various methodologies that can control the association and dissociation of the complexes have been achieved by using pH 13 , electric fields 14 , salt concentrations 15 , the addition of polyelectrolytes 16, 17 , and other additives 18 . Although these methodologies are effective at regulating the enzymatic activity in response to physical or chemical stimuli to a certain extent, the potential of intracellular delivery and enzymatic control in intracellular environments is not yet known. Because the intracellular activity of enzymes plays a crucial role in enzyme-based therapy, strategies for molecular logistics are required to show efficient intracellular delivery as well as enhanced enzymatic activity in the intracellular environment.
We have developed a new modality of biodegradable supermolecules for the intracellular delivery and the subsequent release of biopharmaceuticals based on polyrotaxanes (PRXs) [19] [20] [21] . The PRXs consist of a-cyclodextrins (CDs) threaded along a poly(ethylene glycol) (PEG) chain and a terminal bulky stopper via intracellularly cleavable linkages such as disulfide linkages 21 . The supramolecular structure of cleavable PRXs is sufficiently stable under physiological conditions, whereas the PRXs degrade into their constituent molecules (i.e., PEG and CD) when the terminal linkers are cleaved by intracellular stimuli. We have developed N,N-dimethylaminoethyl (DMAE) group-modified PRXs with terminal disulfide linkages (DMAE-SS-PRXs) as carriers for the intracellular delivery of plasmid DNA (pDNA) [22] [23] [24] and small interfering RNA (siRNA) 25 . The cytocleavable cationic PRXs induce significantly higher gene expression of pDNA or gene silencing efficiency of siRNA than non-cleavable DMAE-PRX through the degradation of the DMAE-SS-PRXs and the efficient intracellular release of their cargos [21] [22] [23] [24] [25] . Thus, it is strongly anticipated that the DMAE-SS-PRXs have great potential as vehicles to achieve efficient intracellular release of active enzymes.
In this study, anionic b-galactosidase (b-gal) (464.5 kDa, pI 5 4.6) was selected as a model enzyme to form a polyelectrolyte complex with the DMAE-SS-PRXs 26 , and the reduction-induced reactivation of enzymes was demonstrated ( Fig. 1) . Furthermore, the intracellular delivery and intracellular enzymatic activity were evaluated in comparison with the non-cleavable DMAE-PRXs and the CPP-based commercial reagent.
Results
Preparation and characterization of DMAE-SS-PRX/b-gal polyelectrolyte complexes. To form a polyelectrolyte complex with the anionic b-gal, the reduction-cleavable DMAE-SS-PRXs were synthesized as summarized in Table 1 . The DMAE-SS-PRX/b-gal complexes were prepared by mixing each solution at various N/C ratios (defined as the molar ratio of the cationic DMAE groups in the DMAE-SS-PRX to the anionic carboxylic acid residues (Asp and Glu) in b-gal). The formation of the complexes was confirmed by native agarose gel electrophoresis ( Fig. 2A) . The b-gal band disappeared at an N/C ratio of 1.5. The diameter and zeta potentials of the resulting complexes were characterized as shown in Fig. 2B . The zeta potential of native b-gal was strongly negative (220 mV), whereas those of the complexes gradually shifted to positive values as the N/C ratio increased. The diameter of the complexes drastically increased to a relatively large diameter (approximately 1 mm) in the N/C ratio range of 0.5 to 3. For the N/C ratios greater than this range, the diameter of the complexes decreased to 45 nm at the N/C ratio of 10.
The enzymatic activity of the DMAE-SS-PRX/b-gal complexes prepared at various N/C ratios was determined by colorimetry using o-nitrophenyl-b-D-galactopyranoside (ONPG) as a substrate (Fig.  2C) . As the N/C ratio was increased, the enzymatic activity of bgal gradually decreased and reached a plateau (approximately 32%) over the N/C ratio of 2. Herein, the DMAE-SS-PRX/b-gal complexes (N/C 2) showed almost identical circular dichroism spectra to the native b-gal ( Fig. 2D) . To determine the kinetic parameters of this reaction, the enzymatic activity of the DMAE-SS-PRX/b-gal complexes was measured at various substrate concentrations ([S]) to make Hanes-Woolf plots ( Supplementary Fig. S2 ) 27, 28 . The V max,app of the enzymatic reaction decreased as the N/C ratio increased, whereas K m,app remained constant ( Supplementary  Table S1 ).
Reduction-induced release of b-gal from complexes. When the DMAE-SS-PRX/b-gal reacts with intracellular reductive molecules such as glutathione (GSH), the supramolecular structure of the DMAE-SS-PRX may dissociate into its constitutive molecules, resulting in the release of native enzymes to recover their activity. To confirm this hypothesis, gel electrophoresis of DMAE-SS-PRX/bgal (N/C 2) was performed after 1 h incubation in various GSH concentrations ( Fig. 3A) . At the same time, a non-cleavable DMAE-PRX with roughly comparable number of threading CDs Supplementary Fig. S1 ). The values in parentheses represent the percentage of CD coverage on the PEG chain, assuming one CD molecule includes two repeating units of ethylene glycol. b Determined by 1 H NMR in D 2 O ( Supplementary Fig. S1 ). c Calculated based on the chemical composition determined by 1 and DMAE groups was tested as a control ( Table 1 and Fig. 3B ). In the case of the DMAE-SS-PRX/b-gal complexes, smeared bands of free enzyme appeared at the GSH concentrations over 1 mM, whereas no band was observed for non-cleavable DMAE-PRX/bgal complexes, even at a GSH concentration of 5 mM. Similarly, the enzymatic activity of the cleavable DMAE-SS-PRX/b-gal and the non-cleavable DMAE-PRX/b-gal complexes (N/C 2) was determined after 1 h incubation in various concentrations of GSH ( Fig. 3C ). In the range of extracellular GSH concentrations (1 to 10 mM) 29 , the enzymatic activity was almost constant (approximately 30 to 40%) for both type of PRXs. When the concentration of GSH increased to intracellular level (. 0.5 mM), the enzymatic activity of the cleavable DMAE-SS-PRX/b-gal recovered completely. Since the b-gal was released from the complexes at a high GSH concentration, the enzymatic activity is thought to be recovered. However, at the GSH concentration greater than 1 mM, the enzymatic activity decreased again, presumably due to denature of the released b-gal at a high GSH concentration ( Supplementary Fig. S4 ). In contrast to the cleavable PRXs, negligible change in the enzymatic activity of the non-cleavable DMAE-PRX/b-gal was observed over the tested GSH concentration range.
Intracellular uptake and activity of the DMAE-SS-PRX/b-gal complexes. To assess the intracellular transduction ability of the DMAE-SS-PRX/b-gal complexes, confocal laser scanning microscopic (CLSM) observation of HeLa cells was performed after a 24 h incubation with samples including FITC-b-gal. As a control, a commercially available cell-penetrating peptide (CPP)-based Xfect reagent was used. To verify the intracellular localization of the FITCb-gal (green), cell nuclei and acidic endosomes/lysosomes were stained with Hoechst 33342 (blue) and LysoTracker Red (red), respectively. As shown in Fig. 4A , negligible fluorescence was observed for the native FITC-b-gal. On the contrary, green spots from the FITC-b-gal were observed in the intracellular regions for Xfect, and most of the green spots were separated from the endosomes/lysosomes (Fig. 4B) . With the PRXs, bright green signals were observed around the perinuclear regions, and they were considered to colocalize with the endosomes/lysosomes for both DMAE-SS-PRX and DMAE-PRX ( Fig. 4C and 4D ). For quantitative comparison, the intracellular uptake level of FITC-b-gal was determined by flow cytometry (Fig. 4E) . The intracellular uptake level of FITC-b-gal was almost the same between the cleavable DMAE-SS-PRX and the non-cleavable DMAE-PRX, and the fluorescence intensities were approximately 30-times higher than the native FITC-b-gal. Additionally, the cleavable DMAE-SS-PRX and non-cleavable DMAE-PRX showed slightly higher intracellular uptake levels of FITC-b-gal than the CPP-based Xfect reagent, even at the low N/C ratio (N/C 2). The enzymatic activity of the DMAE-SS-PRX/b-gal complexes in living cells was evaluated using membrane-permeable TokyoGreenb-Gal (TG-b-gal) as a fluorescent substrate 30, 31 . Fig. 5A -D shows the CLSM images of HeLa cells after incubation with 10 mM TG-b-gal for 30 min. When the cells were treated with free b-gal, no fluorescence was observed ( Fig. 5A) . For the Xfect/b-gal and the noncleavable DMAE-PRX/b-gal, the generation of fluorescent product was observed in both the intracellular and extracellular regions ( Fig. 5B and 5D ). The observed extracellular fluorescence may be due to the diffusion of fluorescent products (2-Me-4OMe TG) into the extracellular medium 32 . On the contrary, a remarkably bright fluorescence was observed in the intracellular region for the cleavable DMAE-SS-PRX/b-gal, indicating its superior enzymatic activity in the intracellular environment ( Fig. 5C ). To determine the fluorescence intensity and to compare the kinetics of intracellular enzymatic reaction, a time-course of the fluorescence intensity change was monitored after the addition of TG-b-gal ( Fig. 5E) . Overall, the cleavable DMAE-SS-PRX/b-gal complex-treated cells showed the largest and most persistent change in fluorescence intensity, consistent with the CLSM observation (Fig. 5C) . The non-cleavable DMAE-PRX/bgal was less effective in intracellular enzymatic activity compared to Xfect. The free b-gal-treated cells showed negligible change in fluorescence intensity.
Next, the effect of the N/C ratio of the DMAE-SS-PRX/b-gal complex on cellular internalization and intracellular enzymatic activity was investigated ( Supplementary Fig. S3 ). The intracellular uptake level of the DMAE-SS-PRX/FITC-b-gal complex increased with the N/C ratio and reached a plateau value over an N/C ratio of 5 ( Supplementary Fig. S3 ). The intracellular enzymatic activity of the DMAE-SS-PRX/b-gal complex also increased with the N/C ratio of the complex ( Supplementary Fig. S3 ).
Therapeutic application of DMAE-SS-PRX/b-gal complexes for enzyme-prodrug therapy. To assess the therapeutic potential of the DMAE-SS-PRX/b-gal complexes, intracellular activation of anticancer prodrug was performed with 5-fluorouridine-59-O-b-Dgalactopyranoside (5-FUR-b-gal), which is a galactosylated analogue of 5-fluorouridine (5-FUR) ( Fig. 6) 33 . The 5-FUR shows dosedependent cytotoxicity against HeLa cells, whereas negligible cytotoxicity was observed for 5-FUR-b-gal ( Fig. 6B) . Because the galactosyl residue of 5-FUR-b-gal is hydrolyzed by b-galactosidase and converted into cytotoxic 5-FUR 33 , intracellular enzymatic activation of 5-FUR-b-gal in the presence of the DMAE-SS-PRX/ b-gal complex was tested by a cell viability assay (Fig. 6C) . Without 
Discussion
Our strategy to activate the therapeutic enzymes delivered in cells includes; (1) intracellular uptake of the enzyme using cleavable PRXs, (2) degradation of the PRXs by the cleavage of the terminal cleavable linkages, and (3) release of the enzymes and the subsequent reactivation of the enzymatic activity (Fig. 1) . In this study, b-gal was selected as a model enzyme because of its potential in clinical application for enzyme-prodrug therapy and enzyme replacement therapy 3, 4 . As seen in Fig. 2A , the b-gal and the DMAE-SS-PRX formed a polyelectrolyte complex upon mixing with an appropriate N/C ratio. At the N/C ratio range of 1 to 5, the DMAE-SS-PRX/b-gal complexes had large diameters and low zeta-potential values, most likely due to the weak electrostatic repulsive force between the complexes through charge neutralization (Fig. 2B) . Over the N/C ratio of 5, the diameter of the complexes decreased. This result suggests that the aggregation of the complexes is prohibited due to their strongly positive charge. When the b-gal forms a polyelectrolyte complex with cationic polymers or nanoparticles, its enzymatic activity often disappears, most likely due to the masking of the active site of the enzymes 16, 17 . Because the active site of b-gal is an anionic Glu residue, the activity of b-gal decreases through the masking of the anionic active site through electrostatic interactions 34, 35 . However, the kinetics study revealed that the DMAE-SS-PRX acts as a non-competitive inhibitor for b-gal ( Supplementary Fig. S2 ). This means that the DMAE-SS-PRX binds to the neighboring anionic amino acid residues of the active site and reduces the catalytic reaction rate while maintaining the binding constant of the substrate 27, 28, 36 . The enzymatic activity of the DMAE-SS-PRX/b-gal complexes was not completely inhibited and still remained at 32% of activity, even at high N/C ratios (Fig. 2C) . In the case of the polyelectrolyte complex between b-gal and cationic polymers such as poly(N,N-diethylaminoethyl methacrylate) or poly(allylamine), the enzymatic activity of b-gal is reported to be completely inhibited 37 . Therefore, the DMAE-SS-PRX is considered to loosely associate with b-gal to allow the access of a substrate to some extent. In the case of the polyelectrolyte complex of the DMAE-SS-PRX with nucleic acids, the DMAE-SS-PRXs form a loosely associated complex with pDNA or siRNA, as revealed by a dye exclusion assay 23, 25 . Taking this fact into account, it is hypothesized that the supramolecular framework of PRXs is a potentially valid and feasible way to form complexes with enzymes without denaturation. Indeed, the b-gal retained its native three dimensional structure throughout the complexation with the DMAE-SS-PRXs (Fig. 2D) . Additionally, the freely mobile nature of threaded CDs in the DMAE-SS-PRX enhances the multivalent electrostatic interaction with anionic enzymes through the improvement of spatial mismatch in the interaction 22 . Therefore, the DMAE-SS-PRX/b-gal complexes are thought to be sufficiently stable for the intracellular delivery.
As shown in Fig. 3C , the activity of the DMAE-SS-PRX/b-gal complexes was recovered upon the addition of GSH, especially at intracellular concentrations (. 0.5 mM) 29 . This result is due to the cleavage of the terminal disulfide linkages of DMAE-SS-PRX and the subsequent release of enzymes, as confirmed by gel electrophoresis (Fig. 3A) . The bands of the released b-gal were smeared, most likely due to the incomplete dissociation of the complexes and/or the inclusion of the hydrophobic amino acid into the cavity of the dethreaded CDs. In contrast to the cleavable DMAE-SS-PRX/b-gal complexes, the non-cleavable DMAE-PRX/b-gal complexes did not release b-gal upon the addition of GSH, resulting in negligible recovery of enzymatic activity (Fig. 3B and 3C ). This fact strongly supports our hypothesis that the GSH-induced release of b-gal is attributable to the recovery of enzymatic activity of the DMAE-SS-PRX/b-gal complexes. At the GSH concentrations greater than 1 mM, the enzymatic activity of the DMAE-SS-PRX/b-gal complexes decreased. This is most likely due to the denaturing of the enzyme by the reaction with high concentrations of GSH. Indeed, the activity of the native b-gal decreased in a GSH concentration-dependent manner (Supplementary Fig. S4) .
The intracellular uptake is of significant importance for inducing the function of exogenous enzymes in cells. Flow cytometric measurements revealed that the DMAE-SS-PRX showed comparable cellular uptake to the CPP-based Xfect (Fig. 4E) . Although the intracellular uptake level of the DMAE-SS-PRX/b-gal complexes increased with the N/C ratio ( Supplementary Fig. S3 ), the N/C ratio of 2 was selected for the cellular experiment to avoid the potential toxic effect derived from excess DMAE-SS-PRX 38, 39 . To confirm the intracellular distribution of delivered b-gal, the CLSM observation was performed. It is revealed that the intracellular localizations of the DMAE-SS-PRX/b-gal complexes and the Xfect/b-gal complexes were completely different, presumably due to a difference in the cellular uptake pathway ( Fig. 4B and 4C) . The Xfect internalizes into cells through macropinocytosis or caveolae-mediated endocytosis 40 . Therefore, Xfect/b-gal is observed as separated from acidic lysosomes because macropinosomes are leaky vesicles, and caveosomes are not involved in the reduction of pH 41 . On the contrary, the DMAE-SS-PRX/b-gal colocalized with the acidic lysosomes, indicating that the DMAE-SS-PRX/b-gal entered into the cells through a different pathway, such as clathrin-mediated endocytosis 42 . There was a negligible difference in the cellular uptake level and intracellular localization between the cleavable DMAE-SS-PRX and the noncleavable DMAE-PRX ( Fig. 4C, 4D, and 4E) , indicating that the terminal linker did not affect the cellular internalization of the complexes.
Herein, the diameter of the DMAE-SS-PRX/b-gal complex at the N/C 2 seems too large for cellular internalization (1 mm). In our CLSM observation, the diameter of the DMAE-SS-PRX/FITC-bgal determined from a pixel in the images was actually smaller than the diamter determined by DLS. Taking this fact into account, two possible reasons arise to explain intercellular trafficking of the complex prepared at the N/C ratio of 2: the dissociation of the complexes in the medium, and over estimation of the diameter by DLS. Since the polyelectrolyte complexes are known to dissociate in the culture medium by simple dilution or interaction with serum proteins 25 , it is plausible that the dissociated complexes are to be internalized into cells. Additionally, since the light scattering intensity is increased with the size, larger particles are detected more sensitive than smaller ones in DLS measurements, which can lead to over estimation of the size. In any cases, it seems obvious that the small particle fraction of the complexes is thought to internalize dominantly into cells. The negative surface charge is also a negative impact in cellular internalization. Although the zeta potential value of the DMAE-SS-PRX/bgal prepared at the N/C 2 is approximately 215 mV, the cellular internalization of the complexes was clearly observed (Fig. 4C) . In the process of cellular internalization, the complexes are first allowed to interact with the surface of the cells, followed by internalized into cells through endocytosis machinery. Thus, it seems that the positively charged particles are allowed to interact more effectively with negatively charged cellular membrane than the neutral or negatively charged particles. However, the cellular internalization of the anionic polyelectrolyte complexes was also observed in various reports 43, 44 . This fact indicates that the anionic complexes are allowed to interact with the receptor proteins on the cellular membrane and involve the endocytosis. Therefore, the DMAE-SS-PRX/b-gal complexes are thought to internalize into cells even at low N/C ratio.
The intracellular activity of the cleavable DMAE-SS-PRX/b-gal was markedly higher than the non-cleavable DMAE-PRX/b-gal activity (Fig. 5C, 5D, and 5E ). This result suggests that DMAE-SS-PRX/b-gal dissociated to release b-gal by intracellular cleavage of DMAE-SS-PRX 22 . The non-cleavable DMAE-PRX/b-gal complexes were retained in the complex form, and their activity was inhibited. The intracellular enzymatic activity of the Xfect/b-gal was also lower than the DMAE-SS-PRX/b-gal activity, despite the comparable cellular uptake levels of the enzyme and a difference in the cellular uptake pathway. To assess this result, the enzymatic activity of Xfect/b-gal was demonstrated using ONPG as a substrate ( Supplementary Fig. 5 ). The enzymatic activity of Xfect/b-gal completely diminished and negligible recovery of the activity was observed upon the addition of GSH. To further evaluate the intracellular activity of the delivered enzymes, the enzyme-prodrug assay was performed using 5-FUR-b-gal as an anticancer prodrug ( Fig. 6) 33 . At a b-gal concentration of 100 nM, the viability of the DMAE-SS-PRX/b-gal and the 5-FUR-b-gal-treated cells was the same as the 5-FUR-treated cells, indicating that most of the 5-FUR-b-gal was converted into cytotoxic 5-FUR in the intracellular environment. Because the intracellular enzymatic activity of the noncleavable DMAE-PRX/b-gal and the Xfect/b-gal was significantly lower than the DMAE-SS-PRX/b-gal ( Fig. 5) , the DMAE-SS-PRX/ b-gal was thought to show the highest anticancer effect.
In summary, the intracellular delivery of enzymes and the subsequent intracellular reactivation of the enzyme were achieved by a polyelectrolyte complex formation with cytocleavable DMAE-SS-PRXs. The intracellularly cleavable DMAE-SS-PRXs provide an attractive technique for delivering therapeutic enzymes into living cells and reactivating the enzymes in response to the intracellular environment.
Methods
Reagents. Poly(ethylene glycol) (PEG) (M n 5 9,810, M w /M n 5 1.02) (Sigma-Aldrich, St. Louis, MO, USA) was used for the synthesis of PRX. The cytocleavable DMAE-SS-PRX and the non-cleavable DMAE-PRX were synthesized as previously reported [22] [23] [24] [25] . The number of threading a-CDs and the number of modified DMAE groups on the PRXs were determined by 1 H NMR spectra ( Supplementary Fig. S1 ) and the characterization of the PRXs was summarized in Table 1 . b-Galactosidase from Escherichia coli (b-gal) (EC 3.2.1.23), L-glutathione (GSH), and o-nitrophenyl-b-Dgalactopyranoside (ONPG) were obtained from Sigma-Aldrich. Fluorescein isothiocyanate-labeled b-galactosidase (FITC-b-gal) was prepared as previously reported 45 . Xfect protein transfection reagent, a cell penetrating peptide-based protein carrier, was obtained from Clontech (Mountain View, CA, USA) and was used according to the manufacturer's instruction. 5-Fluorouridine-59-O-b-Dgalactopyranoside (5-FUR-b-gal) and 5-fluorouridine (5-FUR) were obtained from Carbosynth (Berkshire, UK) and TCI (Tokyo, Japan), respectively.
Preparation and characterization of the DMAE-SS-PRX/b-gal complexes. The bgal was dissolved in 10 mM HEPES buffer (pH 7.4) to prepare a 15 mM stock solution. To this solution, the DMAE-SS-PRXs solution was added at various N/C ratios (molar ratio of the cationic DMAE groups of the DMAE-SS-PRX to the anionic Asp and Glu residues of b-gal) and allowed to sit for 1 h to form the polyelectrolyte complexes (final concentration of b-gal: 2.5 mM). The formation of the DMAE-SS-PRX/b-gal complex was confirmed by native agarose gel electrophoresis. The complex solutions (20 mL) were mixed with BlueJuice gel loading buffer (Invitrogen) (1 mL), and 15 mL of the solutions was applied to 0.8% agarose gel (Sigma-Aldrich). The electrophoresis was performed in TBE buffer (44.5 mM tris, 44.5 mM boronic acid, and 1 mM EDTA) for 20 min at 200 V. The gel was placed in CBB staining solution (0.2% CBB R-250, 10% acetic acid, and 45% methanol) for 10 min, followed by incubation in destaining solution (10% acetic acid and 25% methanol). Similarly, gel electrophoresis of the DMAE-SS-PRX/b-gal and the DMAE-PRX/b-gal complexes (N/C 2) in the presence of GSH was conducted. To the complex solutions, GSH was added at various concentrations and incubated for 1 h. The electrophoresis was performed as described above.
Circular dichroism spectra were recorded on a J-725 spectropolarimeter (Jasco, Tokyo, Japan) at 25uC. The diameter and the zeta potential of the DMAE-SS-PRX/bgal complexes were determined on a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) equipped with a 4 mW He-Ne laser (633 nm). The dynamic light scattering (DLS) measurements were conducted at 25uC at a detection angle of 173u. The obtained autocorrelation functions were analyzed by the CONTIN method to determine number-averaged diameters. The electrophoretic light scattering measurements were performed at 25uC. www.nature.com/scientificreports SCIENTIFIC REPORTS | 3 : 2252 | DOI: 10.1038/srep02252
Enzymatic activity assay. DMAE-SS-PRX/b-gal complexes with various N/C ratios were prepared in a 10 mM HEPES buffer solution (pH 7.4) at a b-gal concentration of 20 nM. The substrate solution (10 mM ONPG in 10 mM HEPES buffer) (225 mL) was added to an equal volume of the DMAE-SS-PRX/b-gal complexes and the b-gal solutions, and a time-course of the increment in absorbance at 410 nm was recorded on a V-550 UV-VIS spectrophotometer (Jasco) for 1 min. The relative enzymatic activity was determined from the initial slope of the absorbance variation derived from the product. Similarly, the enzymatic activity of the DMAE-SS-PRX/b-gal and the DMAE-PRX/b-gal complexes (N/C 2) in the presence of GSH was determined. To the complex solutions, GSH was added at various concentrations. After incubation for 1 h, the enzymatic activity was determined as described above.
